Integra LifeSciences
IART
212 hedge funds and large institutions have $1.32B invested in Integra LifeSciences in 2026 Q2 according to their latest regulatory filings, with 46 funds opening new positions, 72 increasing their positions, 62 reducing their positions, and 32 closing their positions.
87% more capital invested
Capital invested by funds: $705M → $1.32B (+$612M)
44% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 32
16% more repeat investments, than reductions
Existing positions increased: 72 | Existing positions reduced: 62
5% more funds holding
Funds holding: 202 → 212 (+10)
1.73% less ownership
Funds ownership: 95.97% → 94.24% (-1.7%)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$11.4M |
| 2 |
IHAM
Integral Health Asset Management
New York
|
+$7.69M |
| 3 |
BlackRock
New York
|
+$5.1M |
| 4 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$4.88M |
| 5 |
Nuveen
Charlotte,
North Carolina
|
+$4.62M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCMI
Paradigm Capital Management Inc
Albany,
New York
|
-$8.02M |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
-$7.81M |
| 3 |
ICM
Invenomic Capital Management
Boston,
Massachusetts
|
-$6.05M |
| 4 |
Goldman Sachs
New York
|
-$5.64M |
| 5 |
BNP Paribas Financial Markets
Paris,
France
|
-$5.14M |
IART Hedge Fund Activity: Q2 2026 in Review
212 of the 8,287 institutional investors tracked by Wall St. Rank reported a position in Integra LifeSciences (IART) for Q2 2026, worth a combined $1.32B — up 87% from $705M a quarter earlier.
Buyers outnumbered sellers: 46 funds opened new IART positions and 32 closed out — a net gain of 14 holders — while 72 added to existing stakes and 62 trimmed.
The largest buyer was Millennium Management, adding an estimated $11.4M. The largest seller was Paradigm Capital Management Inc, cutting an estimated $8.02M.
- 212 institutional investors held Integra LifeSciences (IART) as of Q2 2026, up from 202 in Q1 2026.
- Funds reported $1.32B of Integra LifeSciences stock for Q2 2026, up 87% quarter-over-quarter.
- 46 funds opened new Integra LifeSciences positions in Q2 2026 and 32 closed out, a net change of +14 holders.
- The largest Integra LifeSciences buyer in Q2 2026 was Millennium Management, an estimated $11.4M added.
- The largest Integra LifeSciences seller in Q2 2026 was Paradigm Capital Management Inc, an estimated $8.02M sold.
Based on aggregated 13F filings for Q2 2026.